Whereas, we demonstrated in a bladder cancer cell model, the TP agonist U46619 induced FOXO3 phosphorylation in a time dependent manner (Figure 2A) and was concurrent with increased activated ERK1/2. This evidence concerns the gene MAPK3 and urinary bladder cancer.